Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
J. Heinonen, T.H. Koskela, E. Soini & O.P. Ryynänen. (2015) Primary-care-based episodes of care and their costs in a three-month follow-up in Finland. Scandinavian Journal of Primary Health Care 33:4, pages 283-290.
Read now
Read now
Erkki J.O. Soini, Glenn Davies, Janne A. Martikainen, Henry X. Hu, Kaan Tunceli & Leo Niskanen. (2010) Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Current Medical Research and Opinion 26:1, pages 25-36.
Read now
Read now
J. Keränen, E.J.O. Soini, O.-P. Ryynänen, K. Hietaniemi & U. Keränen. (2007) Economic evaluation comparing From Home To Operation same day admission and preoperative admission one day prior to the surgery process : a randomized, controlled trial of laparoscopic cholecystectomy. Current Medical Research and Opinion 23:11, pages 2775-2784.
Read now
Read now
J. Paul Leigh & Richard H. White. (2007) An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation. Current Medical Research and Opinion 23:9, pages 2071-2081.
Read now
Read now
Jonas Wallvik, Anders Själander, Lars Johansson, Örjan Bjuhr & Jan-Håkan Jansson. (2007) Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scandinavian Journal of Primary Health Care 25:2, pages 123-128.
Read now
Read now
Articles from other publishers (13)
Mikko Pyykönen, Miika Linna, Markku Tykkyläinen, Eric Delmelle & Tiina Laatikainen. (2021) Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin. BMC Health Services Research 21:1.
Crossref
Crossref
Giorgio Ciminata, Claudia Geue, Peter Langhorne & Olivia Wu. (2020) A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. BMJ Open 10:3, pages e028575.
Crossref
Crossref
Lisa R. Ulrich, Juliana J. Petersen, Karola Mergenthal, Andrea Berghold, Gudrun Pregartner, Rolf Holle & Andrea Siebenhofer. (2019) Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care – results from the PICANT trial. Health Economics Review 9:1.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref
Taru Hallinen, Erkki J. Soini, Miika Linna & Samuli I. Saarni. (2016) Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus 5:1.
Crossref
Crossref
Juan Carlos D?az-Mart?nez, Mauricio Duque-Ram?rez, Jorge Eduardo Mar?n-Vel?squez, Juli?n Miguel Aristiz?bal-Aristiz?bal, Jorge Enrique Vel?squez-V?lez & William Uribe-Arango. (2016) Costos asociados a la fibrilaci?n auricular. Revista Colombiana de Cardiolog?a 23, pages 192-197.
Crossref
Crossref
Maria Rikala, Milka Hauta-Aho, Arja Helin-Salmivaara, Riitta Lassila, Maarit Jaana Korhonen & Risto Huupponen. (2015) Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study. Basic & Clinical Pharmacology & Toxicology 117:2, pages 126-132.
Crossref
Crossref
Erkki J Soini, Miina Leussu & Taru Hallinen. (2013) Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2:1.
Crossref
Crossref
Linnea A. Polgreen & John M. Brooks. (2012) Estimating Incremental Costs with Skew. Applied Health Economics and Health Policy 10:5, pages 319-329.
Crossref
Crossref
S. E. Wolowacz, M. Samuel, V. K. Brennan, J.- G. Jasso-Mosqueda & I. C. Van Gelder. (2011) The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 13:10, pages 1375-1385.
Crossref
Crossref
Anirban Basu, Daniel Polsky & Willard G. Manning. (2011) Estimating treatment effects on healthcare costs under exogeneity: is there a ‘magic bullet’?. Health Services and Outcomes Research Methodology 11:1-2, pages 1-26.
Crossref
Crossref
Andrea L. Jorgensen, Sameh Al-Zubiedi, Jieying Eunice Zhang, Andrew Keniry, Anita Hanson, Dyfrig A. Hughes, Diane van Eker, Lisa Stevens, Karen Hawkins, Cheng H. Toh, Farhad Kamali, Ann K. Daly, David Fitzmaurice, Alison Coffey, Paula R. Williamson, Brian Kevin Park, Panos Deloukas & Munir Pirmohamed. (2009) Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and Genomics 19:10, pages 800-812.
Crossref
Crossref
Mark R Dunbar, Piyush K Upadhyay & Shanmugam Karthikeyan. (2008) The Use of Warfarin as Thromboprophylaxis for Lower Limb Arthroplasty. The Annals of The Royal College of Surgeons of England 90:6, pages 500-503.
Crossref
Crossref